When RFS was compared according to EGFR status, we found a significant difference in RFS between PD-L1-positive and PD-L1-negative cases in patients with EGFR-mutated lung adenocarcinoma (log-rank, p=0.006), but not in patients with EGFR wild-type lung adenocarcinoma (log-rank, p=0.646) (Figures 3B, C). This evidence concerns the gene EGFR and lung adenocarcinoma.